What are Nexlizet and Nexletol, and what do they do in the body?
Nexletol (bempedoic acid) and Nexlizet (bempedoic acid + ezetimibe) are cholesterol-lowering medicines used to reduce LDL cholesterol in people with hyperlipidemia, including those who need additional LDL-lowering beyond statins or who cannot take statins. Their mechanism centers on blocking two different steps in the cholesterol pathway: cholesterol synthesis in the liver (via bempedoic acid) and cholesterol absorption from the intestine (via ezetimibe).
How does bempedoic acid (Nexletol) work?
Bempedoic acid lowers LDL cholesterol by inhibiting ATP citrate lyase, an enzyme involved in the liver’s cholesterol synthesis pathway. By blocking this step, it reduces the production of cholesterol inside liver cells, which increases LDL receptor activity and leads to greater clearance of LDL cholesterol from the bloodstream.
How does ezetimibe (part of Nexlizet) work?
Ezetimibe lowers LDL cholesterol by inhibiting intestinal cholesterol absorption. It reduces the amount of cholesterol taken up from the gut into the body, which contributes to less cholesterol available for the liver and helps increase LDL receptor-mediated clearance of LDL cholesterol from the blood.
How do Nexlizet’s two mechanisms work together?
Because Nexlizet combines bempedoic acid (reduces liver cholesterol synthesis via ATP citrate lyase inhibition) with ezetimibe (reduces intestinal cholesterol absorption), it attacks LDL cholesterol from two angles at once: less cholesterol is made in the liver and less cholesterol enters from the intestine. This paired mechanism is why Nexlizet is used when additional LDL-lowering is needed.
What patients typically take them for (and why the MOA matters)?
Clinicians choose this combination approach for patients who still have elevated LDL cholesterol despite statin therapy or who require extra LDL reduction. The distinct mechanisms can produce additive LDL-lowering compared with using only one pathway-targeting strategy.
Sources
No external sources were provided in the prompt. If you want, share the exact prescribing information excerpt(s) you’re using (or your DrugPatentWatch.com link), and I can map the MOA to those specific statements and cite them precisely.